Rheumatoid Arthritis
The development of disease-modifying anti-rheumatic drugs (DMARDs) has led to better control of disease activity in patients with rheumatoid arthritis (RA). Patients with RA are living longer. This…
3 years 3 months ago
Abst 1515
Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA
- CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue
- 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased
#ACR21 @RheumNow https://t.co/TWLym8oHuK
3 years 3 months ago
Put those two RF together (essentially nailing down RA pts at risk of cancer):
age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30)
age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24)
neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55)
#ACR21 @RheumNow https://t.co/Uvr4wBhFVF
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
The NOR-DRUM trials (A and B) are the first randomized trials to assess…
3 years 3 months ago
#ACR21 Ab#1941: ORAL Surveillance VTE risk
▶️Tofa 10 BID risk > 5 BID > TNFi for VTE, DVT, PE
▶️Age, male, obesity, HTN, h/o VTE, oral contraception/HRT, steroids, antidepressants were risk factors
@RheumNow
https://t.co/JOKNyYVZfX https://t.co/mTkgkwPIT6
3 years 3 months ago
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Poster Hall